At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations
In Brief
A Phase 2 clinical trial evaluating Erlotinib for Non-small Cell Lung Cancer. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
Erlotinib is a drug which targets non small cell lung cancer with a genetic change (mutation) in the epidermal growth factor receptor (EGFR). This drug has been used in other cancer research studies and information from those studies suggests that Erlotinib can control the growth of these cancer cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartFeb 2010
Primary CompletionMay 2015
Study CompletionJan 2017
TodayJul 2026
First PostedOct 19, 2009
Enrollment StartFeb 1, 2010
Primary CompletionMay 1, 2015
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 16.7 years ago
Interventions
Erlotinibdrug